Table 2.

Regulation of miRNA expression by histone modifiers.

miRNAs	Cancer type	Decrease/increase	Type of histone modification	Reference
miR-127	Primary human tumors	Decrease	Increased histone H3 acetylation and H3-K4 methylation	[37]
miRNA-1260b	Prostate cancer cells	Increase	Increased H3K9-me2, H3K9me3 and H3K27me3	[38]
miR-124a	Acute lymphoblastic leukemia	Decrease	Decreased levels of 3mk4H3 and AcH3 and increased levels of 2mK9H3, 3mK9H3, and 3mK27H3	[39]
let-7e, miR-1246, miR-1826, and miR-361-5p	Breast cancer	Decrease	Decreased H3K4me3	[40]
miR-615	Prostate cancer	Increase	Increased H3K9 acetylation	[41]
miR-29	B-cell lymphomas	Decrease	Increased histone deacetylation and trimethylation	[42]
miR-15a, miR-16, and miR-29b	Chronic lymphocytic leukemia	Decrease	Increased histone deacetylation	[36]
miR-15a and miR-16	Non-Hodgkin B-cell lymphomas	Decrease	Increased histone deacetylation (HDAC3)	[43]
miR-31	Breast cancer	Decrease	Increased methylation	[44]
miR-31	Adult T-cell leukemia	Decrease	Increased H3K9 and H3K27 methylation	[45]
miR-23a	Human leukemic Jurkat cells	Decrease	Increased deacetylation (HDAC4)	[46]
miR-139-5p, miR-125b, miR-101, let-7c, and miR-200b	Hepatocellular carcinoma	Decrease	Increased histone H3 lysine 27 (H3K27) trimethylating (EZH2)	[47]
miR-449	Hepatocellular carcinoma	Decrease	Increased histone deacetylation (HDAC1–3)	[48]
miR-224	Hepatocellular carcinoma	Increase	Increased histone acetyltation (Ep300)	[30]
miR-155	Breast cancer	Increase	Decreased H2A and H3 deacetylation (HDAC)	[31]